BCRX
HEALTHCAREBioCryst Pharmaceuticals Inc
AI Insight
What's Moving BCRX Today?
No stock-specific AI insight has been generated for BCRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.00$10.32
$9.31
Fundamentals
Market Cap$2.3B
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-1,925.0%
Profit Margin-51.7%
Debt / Equity—
Trading
Volume5.1M
Avg Volume (10D)—
Shares Outstanding254.2M
BCRX News
27 articles- Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board payStock Titan·Jun 16, 2026
- BioCryst (BCRX) director Vincent Milano receives stock and option grantsStock Titan·Jun 16, 2026
- BioCryst highlights efficacy gains across hereditary angioedema portfoliografa.com·Jun 12, 2026
- BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingYahoo Finance·Jun 12, 2026
- Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?Yahoo Finance·Jun 11, 2026
- WCG Appoints Anthony Doyle as Chief Financial Officer to Support Continued Growth and Operational ScaleYahoo Finance·Jun 11, 2026
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 9, 2026
- BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial AdvancesMarketbeat·Jun 6, 2026
- BioCryst (BCRX) director awarded stock in lieu of cash retainerStock Titan·Jun 2, 2026
- BIOCRYST (BCRX) Board Chair Vincent Milano receives stock grant as retainer payStock Titan·Jun 2, 2026
- BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingYahoo Finance·May 27, 2026
- Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence pushTipRanks·May 21, 2026
- BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026Yahoo Finance·May 13, 2026
- BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?Yahoo Finance·May 12, 2026
- A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing DealYahoo Finance·May 12, 2026
- BioCryst (BCRX) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- BioCryst Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- BioCryst Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary AngioedemaYahoo Finance·May 4, 2026
- Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price GainsYahoo Finance·May 3, 2026
- RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in BiotechYahoo Finance·May 1, 2026
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped TooYahoo Finance·Apr 29, 2026
- BioCryst to Present at Upcoming Investor ConferencesYahoo Finance·Apr 28, 2026
- BioCryst to Report First Quarter 2026 Financial Results on May 6Yahoo Finance·Apr 15, 2026
- BioCryst Appoints Sandeep M. Menon Chief Research and Development OfficerGlobeNewswire Inc.·Apr 6, 2026
All 27 articles loaded
Price Data
Open$9.18
Previous Close$9.31
Day High$9.50
Day Low$9.10
52 Week High$10.32
52 Week Low$6.00
52-Week Range
$6.00$10.32
$9.31
Fundamentals
Market Cap$2.3B
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-1,925.0%
Profit Margin-51.7%
Debt / Equity—
Trading
Volume5.1M
Avg Volume (10D)—
Shares Outstanding254.2M
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—